A Long Term Safety Study of Degarelix in Patients With Prostate Cancer

Summary

Patients that completed any of the trials; CS27 (NCT00738673), CS28 (NCT00831233), CS30 (NCT00833248) or CS31 (NCT00884273) will be given the opportunity to receive monthly doses of degarelix until the drug is launched in their country. Safety parameters such as electrocardiogram (ECG), blood and urine samples and general health state will be studied. Note: patients completing the CS27 trial did not participate in the CS34 trial.

Timeline

Start

2009-08

Primary completion

2011-11

Completion

2011-12

Drugs

Indications